Cargando…
Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial
BACKGROUND: Statins have anti-inflammatory and immunomodulatory properties in addition to lipid-lowering effects. OBJECTIVES: To report the 12-month extension of a phase II trial evaluating the efficacy, safety and tolerability of atorvastatin 40 mg/d added to interferon beta-1b (IFNB-1b) in relapsi...
Autores principales: | Kamm, Christian P., El-Koussy, Marwan, Humpert, Sebastian, Findling, Oliver, Burren, Yuliya, Schwegler, Guido, Donati, Filippo, Müller, Martin, Müller, Felix, Slotboom, Johannes, Kappos, Ludwig, Naegelin, Yvonne, Mattle, Heinrich P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907426/ https://www.ncbi.nlm.nih.gov/pubmed/24497963 http://dx.doi.org/10.1371/journal.pone.0086663 |
Ejemplares similares
-
Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial
por: Kamm, Christian Philipp, et al.
Publicado: (2012) -
SWiss Atorvastatin and Interferon Beta-1b Trial In Multiple Sclerosis (SWABIMS) - rationale, design and methodology
por: Kamm, Christian P, et al.
Publicado: (2009) -
Variables Related to Working Capability among Swiss Patients with Multiple Sclerosis—A Cohort Study
por: Findling, Oliver, et al.
Publicado: (2015) -
Practice Effects of Mobile Tests of Cognition, Dexterity, and Mobility on Patients With Multiple Sclerosis: Data Analysis of a Smartphone-Based Observational Study
por: Woelfle, Tim, et al.
Publicado: (2021) -
Measuring and Validating the Levels of Brain-Derived Neurotrophic Factor in Human Serum
por: Naegelin, Yvonne, et al.
Publicado: (2018)